<DOC>
	<DOC>NCT02678299</DOC>
	<brief_summary>This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamsutine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P[R]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.</brief_summary>
	<brief_title>Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients with a histologically confirmed relapse of an aggressive lymphoma of T or Bcell phenotype (including follicular lymphoma grade 3b). For excluded histological entities see 'Exclusion criteria' Phase 1 + Phase 2 'fit' patients: Age 1870 years at the time of inclusion ECOG PS 01 at protocol entry Deemed 'fit' by the treating physician Phase 2 'frail' patients: Age 7185 years at the time of inclusion and/or ECOG PS 23 at protocol entry and/or Deemed 'frail' by the treating physician At least six months response duration since last given course of treatment Estimated life expectancy of 3 months or longer Measurable disease Hemoglobin ≥ 8 g/dL (≥5 mmol/l) Platelets ≥ 100 x 109/L; ≥ 75 x 109/L permitted if bone marrow involvement Absolute neutrophil count ≥ 1.5 x 109/L; ≥ 1.0 x 109/L permitted if documented bone marrow involvement Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); patients with proven Gilbert's syndrome (≤ 5 x ULN) may be enrolled. Serum glutamicoxaloacetic transaminase (AST) and/or serum glutamicpyruvic transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if elevation is due to hepatic involvement by lymphoma Serum creatinine ≤ 2 x ULNb Women of childbearing potential must use safe anticonception (e.g. contraceptive pills, intrauterine devices etc.) during the study and 12 months after the last administration of study drugs Male patients must use contraception for the duration of the study and 6 months after the last administration of study drugs if his partner is of childbearing potential Written informed consent Patients with primary refractory disease (e.g. progressing under platinumcontaining or similar salvage therapy) defined as &lt; 6 months response duration from last given course of treatment. Highdose therapy with autologous stem cell rescue within the last 6 months prior to study entry. Following Tcell lymphoma entities: Tcell lymphoblastic lymphoma Hepatosplenic Tcell lymphoma Extranodal NK/T, nasal type Subcutaneous panniculitislike Primary cutaneous Tcell lymphoma Primary leukemic Tcell lymphoma Following Bcell lymphoma entities: Transformed indolent Bcell lymphomas Posttransplant Bcell lymphoproliferative disease HIVassociated Bcell lymphoma Concurrent severe and/or uncontrolled medical disease which is not lymphomarelated Left ventricular ejection fraction (LVEF) &lt; 45% Suspected or documented central nervous system involvement by NHL Patients known to be antigen positive for HIV and/or hepatitis B and/or hepatitis C Patients with active, uncontrolled infections Vaccination with live, attenuated vaccines within 4 weeks of inclusion Pregnant and/or breastfeeding women History of active cancer during the past 5 years, except basal carcinoma of the skin or stage 0 cervical carcinoma Known hypersensitivity to one or more of the study drugs Unwillingness or inability to comply with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>